Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?

OBJECTIVES: Advancements in non-small cell lung cancer treatment based on targeted therapies have made the differentiation between adenocarcinoma and squamous cell carcinoma increasingly important. Pathologists are challenged to make the correct diagnosis in small specimens. We studied the accuracy...

Full description

Bibliographic Details
Main Authors: Fabiola Del Carlo Bernardi, Marcela Del Carlo Bernardi, Teresa Takagaki, Sheila Aparecida Coelho Siqueira, Marisa Dolhnikoff
Format: Article
Language:English
Published: Elsevier España 2018-10-01
Series:Clinics
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000100278&lng=en&tlng=en
_version_ 1828827350144385024
author Fabiola Del Carlo Bernardi
Marcela Del Carlo Bernardi
Teresa Takagaki
Sheila Aparecida Coelho Siqueira
Marisa Dolhnikoff
author_facet Fabiola Del Carlo Bernardi
Marcela Del Carlo Bernardi
Teresa Takagaki
Sheila Aparecida Coelho Siqueira
Marisa Dolhnikoff
author_sort Fabiola Del Carlo Bernardi
collection DOAJ
description OBJECTIVES: Advancements in non-small cell lung cancer treatment based on targeted therapies have made the differentiation between adenocarcinoma and squamous cell carcinoma increasingly important. Pathologists are challenged to make the correct diagnosis in small specimens. We studied the accuracy of an immunohistochemical panel in subclassifying non-small cell lung cancer in routine small biopsies and compared the results with the diagnosis from resected lung specimens, autopsy samples or biopsied/resected metastases. METHODS: In total, 340 lung cancer biopsies were investigated for the expression of CK5, TTF1, p63 and surfactant. RESULTS: We characterized 166 adenocarcinomas and 124 squamous cell carcinomas. Overall, 85% of cases displayed binary staining (TTF1 positive/p63 negative, and vice versa). The diagnoses of ten cases with a morphology that indicated a specific tumor subtype were changed after immunohistochemistry (IHC). A second specimen was available for 71 patients, and the first diagnosis at biopsy was confirmed in 95% of these cases. Most non-small cell lung cancer cases present a binary immunohistochemical profile in small biopsies, contributing to good diagnostic accuracy with routine markers. In a small proportion of cases, the diagnosis can be changed after IHC even when the morphological aspects indicate one specific tumor subtype. CONCLUSIONS: We recommend that routine small biopsies of lung cancer without classic morphology should be subjected to a minimum immunohistochemical panel to differentiate adenocarcinoma from squamous cell carcinoma.
first_indexed 2024-12-12T14:57:42Z
format Article
id doaj.art-d84cf94a5cf64d1dbcb33ee66f5929d1
institution Directory Open Access Journal
issn 1980-5322
language English
last_indexed 2024-12-12T14:57:42Z
publishDate 2018-10-01
publisher Elsevier España
record_format Article
series Clinics
spelling doaj.art-d84cf94a5cf64d1dbcb33ee66f5929d12022-12-22T00:20:52ZengElsevier EspañaClinics1980-53222018-10-0173010.6061/clinics/2018/e361S1807-59322018000100278Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?Fabiola Del Carlo BernardiMarcela Del Carlo BernardiTeresa TakagakiSheila Aparecida Coelho SiqueiraMarisa DolhnikoffOBJECTIVES: Advancements in non-small cell lung cancer treatment based on targeted therapies have made the differentiation between adenocarcinoma and squamous cell carcinoma increasingly important. Pathologists are challenged to make the correct diagnosis in small specimens. We studied the accuracy of an immunohistochemical panel in subclassifying non-small cell lung cancer in routine small biopsies and compared the results with the diagnosis from resected lung specimens, autopsy samples or biopsied/resected metastases. METHODS: In total, 340 lung cancer biopsies were investigated for the expression of CK5, TTF1, p63 and surfactant. RESULTS: We characterized 166 adenocarcinomas and 124 squamous cell carcinomas. Overall, 85% of cases displayed binary staining (TTF1 positive/p63 negative, and vice versa). The diagnoses of ten cases with a morphology that indicated a specific tumor subtype were changed after immunohistochemistry (IHC). A second specimen was available for 71 patients, and the first diagnosis at biopsy was confirmed in 95% of these cases. Most non-small cell lung cancer cases present a binary immunohistochemical profile in small biopsies, contributing to good diagnostic accuracy with routine markers. In a small proportion of cases, the diagnosis can be changed after IHC even when the morphological aspects indicate one specific tumor subtype. CONCLUSIONS: We recommend that routine small biopsies of lung cancer without classic morphology should be subjected to a minimum immunohistochemical panel to differentiate adenocarcinoma from squamous cell carcinoma.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000100278&lng=en&tlng=enAdenocarcinomaLung Cancerp63Squamous Cell CarcinomaTTF1
spellingShingle Fabiola Del Carlo Bernardi
Marcela Del Carlo Bernardi
Teresa Takagaki
Sheila Aparecida Coelho Siqueira
Marisa Dolhnikoff
Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?
Clinics
Adenocarcinoma
Lung Cancer
p63
Squamous Cell Carcinoma
TTF1
title Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?
title_full Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?
title_fullStr Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?
title_full_unstemmed Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?
title_short Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?
title_sort lung cancer biopsy can diagnosis be changed after immunohistochemistry when the h e based morphology corresponds to a specific tumor subtype
topic Adenocarcinoma
Lung Cancer
p63
Squamous Cell Carcinoma
TTF1
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000100278&lng=en&tlng=en
work_keys_str_mv AT fabioladelcarlobernardi lungcancerbiopsycandiagnosisbechangedafterimmunohistochemistrywhenthehebasedmorphologycorrespondstoaspecifictumorsubtype
AT marceladelcarlobernardi lungcancerbiopsycandiagnosisbechangedafterimmunohistochemistrywhenthehebasedmorphologycorrespondstoaspecifictumorsubtype
AT teresatakagaki lungcancerbiopsycandiagnosisbechangedafterimmunohistochemistrywhenthehebasedmorphologycorrespondstoaspecifictumorsubtype
AT sheilaaparecidacoelhosiqueira lungcancerbiopsycandiagnosisbechangedafterimmunohistochemistrywhenthehebasedmorphologycorrespondstoaspecifictumorsubtype
AT marisadolhnikoff lungcancerbiopsycandiagnosisbechangedafterimmunohistochemistrywhenthehebasedmorphologycorrespondstoaspecifictumorsubtype